Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing

Eur J Clin Pharmacol. 2023 Dec;79(12):1709-1711. doi: 10.1007/s00228-023-03583-4. Epub 2023 Oct 21.

Abstract

Methods: Fifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 µg/h) for five consecutive weeks, starting two weeks prior to the surgery. Simultaneous plasma and cerebrospinal fluid (CSF) samples were collected during spinal anesthesia.

Results: Median buprenorphine plasma and CSF concentrations at steady-state were 54 pg/mL (range 8.6 - 167 pg/mL) and 1.6 pg/mL (0.30 - 7.3 pg/mL), respectively. The median CSF/plasma -ratio was 3% (range 0.35 - 16%). Large between-subject variability was observed in the measured buprenorphine concentrations within the study population.

Keywords: Buprenorphine; Cerebrospinal fluid; Plasma; Transdermal.

MeSH terms

  • Administration, Cutaneous
  • Analgesics, Opioid
  • Buprenorphine*
  • Humans
  • Osteoarthritis*
  • Transdermal Patch

Substances

  • Buprenorphine
  • Analgesics, Opioid